Challenges in Clinical Design of Immunotherapy Trials for Malignant Glioma

Neurosurgery Clinics of North America

Volumn 21, Issue 1, 2010, Pages 201-214

  Rolle, Cleo E ^a   Sengupta, Sadhak ^a   Lesniak, Maciej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Brain tumors; Clinical trials; Cytokines; Dendritic cells; Glioblastoma multiforme (GBM); Immunotherapy; Vaccines

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AP 12009; BCG VACCINE; CANCER ANTIBODY; CARMUSTINE; CD3 ANTIBODY; CDX 110; CINTREDEKIN BESUDOTOX; COMPLEMENTARY RNA; CYTOKINE; DCVAX; DENDRITIC CELL VACCINE; GLYCOPROTEIN GP 96; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; INTERFERON; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 2; INTERLEUKIN 4 RECEPTOR; MESSENGER RNA; PEPTIDE VACCINE; PLACEBO; STAT3 PROTEIN; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA2; TUMOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WP 1066;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTATION; APOPTOSIS; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CARCINOGENICITY; CELL THERAPY; CELLULAR IMMUNITY; CHILL; CLINICAL TRIAL; CONFUSION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG FEVER; DRUG TARGETING; EDEMA; EFFECTOR CELL; GENE TARGETING; GLIOBLASTOMA; GLIOMA; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOSTIMULATION; KILLER CELL; MYALGIA; NEUROSURGERY; NEUROTOXICITY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN VARIANT; RECURRENT CANCER; REGULATORY T LYMPHOCYTE; REVIEW; SURVIVAL RATE; SURVIVAL TIME;

BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOBLASTOMA; GLIOMA; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; IMMUNOTHERAPY, ADOPTIVE; RESEARCH DESIGN;

EID: 70450196586     PISSN: 10423680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nec.2009.08.002     Document Type: Review

References (120)

1. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 10 (2005) 987-996
2. Sampson J.H., Brady M.L., Petry N.A., et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Neurosurgery 60 2 Suppl 1 (2007) ONS89-ONS98 [discussion: ONS98-89]
3. El Andaloussi A., Han Y., and Lesniak M.S. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg 105 3 (2006) 430-437
4. El Andaloussi A., and Lesniak M.S. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol 8 3 (2006) 234-243
5. Fecci P.E., Mitchell D.A., Whitesides J.F., et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66 6 (2006) 3294-3302
6. Abou-Ghazal M., Yang D.S., Qiao W., et al. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res 14 24 (2008) 8228-8235
7. Libermann T.A., Nusbaum H.R., Razon N., et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313 5998 (1985) 144-147
8. Bigner S.H., Humphrey P.A., Wong A.J., et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 50 24 (1990) 8017-8022
9. Sonabend A.M., Dana K., and Lesniak M.S. Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma. Expert Rev Anticancer Ther 7 Suppl 12 (2007) S45-S50
10. Heimberger A.B., Sun W., Hussain S.F., et al. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol 10 1 (2008) 98-103
11. Frederick L., Wang X.Y., Eley G., et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60 5 (2000) 1383-1387
12. Heimberger A.B., Hlatky R., Suki D., et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11 4 (2005) 1462-1466
13. Sok J.C., Coppelli F.M., Thomas S.M., et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12 17 (2006) 5064-5073
14. Okamoto I., Kenyon L.C., Emlet D.R., et al. Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci 94 1 (2003) 50-56
15. Belli F., Testori A., Rivoltini L., et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 20 20 (2002) 4169-4180
16. Batra S.K., Castelino-Prabhu S., Wikstrand C.J., et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 6 10 (1995) 1251-1259
17. Huang H.S., Nagane M., Klingbeil C.K., et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272 5 (1997) 2927-2935
18. Boockvar J.A., Kapitonov D., Kapoor G., et al. Constitutive EGFR signaling confers a motile phenotype to neural stem cells. Mol Cell Neurosci 24 4 (2003) 1116-1130
19. Pedersen M.W., Tkach V., Pedersen N., et al. Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Int J Cancer 108 5 (2004) 643-653
20. Lammering G., Hewit T.H., Holmes M., et al. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity. Clin Cancer Res 10 19 (2004) 6732-6743
21. Nagane M., Coufal F., Lin H., et al. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56 21 (1996) 5079-5086
22. Montgomery R.B., Guzman J., O'Rourke D.M., et al. Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. J Biol Chem 275 23 (2000) 17358-17363
23. Lammering G., Hewit T.H., Valerie K., et al. EGFRvIII-mediated radioresistance through a strong cytoprotective response. Oncogene 22 36 (2003) 5545-5553
24. Akasaki Y., Liu G., Chung N.H., et al. Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol 173 7 (2004) 4352-4359
25. Shinojima N., Tada K., Shiraishi S., et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63 20 (2003) 6962-6970
26. Heimberger A.B., Archer G.E., Crotty L.E., et al. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 50 1 (2002) 158-164 [discussion: 164-6]
27. Heimberger A.B., Crotty L.E., Archer G.E., et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 9 11 (2003) 4247-4254
28. Humphrey P.A., Wong A.J., Vogelstein B., et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A 87 11 (1990) 4207-4211
29. Johns T.G., Stockert E., Ritter G., et al. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer 98 3 (2002) 398-408
30. Jungbluth A.A., Stockert E., Huang H.J., et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A 100 2 (2003) 639-644
31. Kuan C.T., Wikstrand C.J., Archer G., et al. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. Int J Cancer 88 6 (2000) 962-969
32. Perera R.M., Narita Y., Furnari F.B., et al. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 11 17 (2005) 6390-6399
33. Sampson J.H., Crotty L.E., Lee S., et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A 97 13 (2000) 7503-7508
34. Wikstrand C.J., Stanley S.D., Humphrey P.A., et al. Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor receptor associated with gliomas. J Neuroimmunol 46 1-2 (1993) 165-173
35. Ochiai H., Archer G.E., Herndon II J.E., et al. EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells. Cancer Immunol Immunother 57 1 (2008) 115-121
36. Wu A.H., Xiao J., Anker L., et al. Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. J Neurooncol 76 1 (2006) 23-30
37. Purev E., Cai D., Miller E., et al. Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R). J Immunol 173 10 (2004) 6472-6480
38. Sampson J.H., Archer G.E., Mitchell D.A., et al. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 20 5 (2008) 267-275
39. Eguchi J., Hatano M., Nishimura F., et al. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. Cancer Res 66 11 (2006) 5883-5891
40. Okano F., Storkus W.J., Chambers W.H., et al. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res 8 9 (2002) 2851-2855
41. Joshi B.H., Leland P., Asher A., et al. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures. Cancer Res 61 22 (2001) 8058-8061
42. Joshi B.H., Leland P., Silber J., et al. IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein. Br J Cancer 86 2 (2002) 285-291
43. Kawakami K., Leland P., and Puri R.K. Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells. Cancer Res 60 11 (2000) 2981-2987
44. Obiri N.I., Hillman G.G., Haas G.P., et al. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest 91 1 (1993) 88-93
45. Obiri N.I., Siegel J.P., Varricchio F., et al. Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin Exp Immunol 95 1 (1994) 148-155
46. Puri R.K., Leland P., Kreitman R.J., et al. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein. Int J Cancer 58 4 (1994) 574-581
47. Wheeler C.J., Das A., Liu G., et al. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 10 16 (2004) 5316-5326
48. Yu J.S., Liu G., Ying H., et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64 14 (2004) 4973-4979
49. Liau L.M., Black K.L., Martin N.A., et al. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case report. Neurosurg Focus 9 6 (2000) e8
50. Heimberger A.B., Crotty L.E., Archer G.E., et al. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 103 1 (2000) 16-25
51. de Vleeschouwer S., Rapp M., Sorg R.V., et al. Dendritic cell vaccination in patients with malignant gliomas: current status and future directions. Neurosurgery 59 5 (2006) 988-999 [discussioin: 999-1000]
52. Wheeler C.J., and Black K.L. DCVax-Brain and DC vaccines in the treatment of GBM. Expert Opin Investig Drugs 18 4 (2009) 509-519
53. Parajuli P., Mathupala S., and Sloan A.E. Systematic comparison of dendritic cell-based immunotherapeutic strategies for malignant gliomas: in vitro induction of cytolytic and natural killerlike T cells. Neurosurgery 55 5 (2004) 1194-1204
54. Srivastava P.K., and Maki R.G. Stress-induced proteins in immune response to cancer. Curr Top Microbiol Immunol 167 (1991) 109-123
55. Udono H., and Srivastava P.K. Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med 178 4 (1993) 1391-1396
56. Udono H., and Srivastava P.K. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J Immunol 152 11 (1994) 5398-5403
57. Bethke K., Staib F., Distler M., et al. Different efficiency of heat shock proteins (HSP) to activate human monocytes and dendritic cells: superiority of HSP60. J Immunol 169 11 (2002) 6141-6148
58. Binder R.J., Harris M.L., Menoret A., et al. Saturation, competition, and specificity in interaction of heat shock proteins (hsp) gp96, hsp90, and hsp70 with CD11b+ cells. J Immunol 165 5 (2000) 2582-2587
59. Parsa A, Crane C, Wilson S, et al. Autologous tumor derived gp96 evokes a tumor specific immune response in recurrent glioma patients that correlates with clinical response to therapy. Paper presented at: AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics (C274). San Francisco (CA), October 22-26, 2007.
60. Cohen L., de Moor C., Parker P.A., et al. Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccine. Urol Oncol 7 3 (2002) 119-124
61. Cohen L., Parker P.A., Sterner J., et al. Quality of life in patients with malignant melanoma participating in a phase I trial of an autologous tumour-derived vaccine. Melanoma Res 12 5 (2002) 505-511
62. Pilla L., Patuzzo R., Rivoltini L., et al. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother 55 8 (2006) 958-968
63. Li G., Hu Y.S., Li X.G., et al. Expression and switching of TH1/TH2 type cytokines gene in human gliomas. Chin Med Sci J 20 4 (2005) 268-272
64. Roussel E., Gingras M.C., Grimm E.A., et al. Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clin Exp Immunol 105 2 (1996) 344-352
65. Bodmer S., Strommer K., Frei K., et al. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol 143 10 (1989) 3222-3229
66. Tada T., Yabu K., and Kobayashi S. Detection of active form of transforming growth factor-beta in cerebrospinal fluid of patients with glioma. Jpn J Cancer Res 84 5 (1993) 544-548
67. de Martin R., Haendler B., Hofer-Warbinek R., et al. Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. EMBO J 6 12 (1987) 3673-3677
68. Huettner C., Paulus W., and Roggendorf W. Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol 146 2 (1995) 317-322
69. Colombo F., Barzon L., Franchin E., et al. Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther 12 10 (2005) 835-848
70. Kruse C.A., Cepeda L., Owens B., et al. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother 45 2 (1997) 77-87
71. Wrann M., Bodmer S., de Martin R., et al. T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. EMBO J 6 6 (1987) 1633-1636
72. Hau P., Jachimczak P., Schlingensiepen R., et al. Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 17 2 (2007) 201-212
73. Olson J.J., McKenzie E., Skurski-Martin M., et al. Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme. J Neurooncol 90 3 (2008) 293-299
74. Buckner J.C., Brown L.D., Kugler J.W., et al. Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. J Neurosurg 82 3 (1995) 430-435
75. Buckner J.C., Schomberg P.J., McGinnis W.L., et al. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer 92 2 (2001) 420-433
76. Yong Z., Chang L., Mei Y.X., et al. Role and mechanisms of CD4+CD25+ regulatory T cells in the induction and maintenance of transplantation tolerance. Transpl Immunol 17 2 (2007) 120-129
77. Brusko T.M., Putnam A.L., and Bluestone J.A. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev 223 (2008) 371-390
78. Bayer A.L., Yu A., and Malek T.R. Function of the IL-2R for thymic and peripheral CD4+CD25+ Foxp3+ T regulatory cells. J Immunol 178 7 (2007) 4062-4071
79. Ichihara F., Kono K., Takahashi A., et al. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9 12 (2003) 4404-4408
80. Liyanage U.K., Moore T.T., Joo H.G., et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169 5 (2002) 2756-2761
81. Okita R., Saeki T., Takashima S., et al. CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep 14 5 (2005) 1269-1273
82. Hussain S.F., Yang D., Suki D., et al. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 8 3 (2006) 261-279
83. Grauer O.M., Nierkens S., Bennink E., et al. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 121 1 (2007) 95-105
84. Takahashi Y., Onda M., Tanaka N., et al. Establishment and characterization of two new rectal neuroendocrine cell carcinoma cell lines. Digestion 62 4 (2000) 262-270
85. Manzotti C.N., Tipping H., Perry L.C., et al. Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells. Eur J Immunol 32 10 (2002) 2888-2896
86. Tang Q., Boden E.K., Henriksen K.J., et al. Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol 34 11 (2004) 2996-3005
87. Pae H.O., Oh G.S., Choi B.M., et al. Differential expressions of heme oxygenase-1 gene in CD25- and CD25+ subsets of human CD4+ T cells. Biochem Biophys Res Commun 306 3 (2003) 701-705
88. Choi B.M., Pae H.O., Jeong Y.R., et al. Critical role of heme oxygenase-1 in Foxp3-mediated immune suppression. Biochem Biophys Res Commun 327 4 (2005) 1066-1071
89. Choi B.M., Pae H.O., Jeong Y.R., et al. Overexpression of heme oxygenase (HO)-1 renders Jurkat T cells resistant to fas-mediated apoptosis: involvement of iron released by HO-1. Free Radic Biol Med 36 7 (2004) 858-871
90. Song R., Zhou Z., Kim P.K., et al. Carbon monoxide promotes Fas/CD95-induced apoptosis in Jurkat cells. J Biol Chem 279 43 (2004) 44327-44334
91. Curtin J.F., Candolfi M., Fakhouri T.M., et al. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One 3 4 (2008) e1983
92. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 109 9 (2002) 1139-1142
93. Brantley E.C., and Benveniste E.N. Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res 6 5 (2008) 675-684
94. Chung C.D., Liao J., Liu B., et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 278 5344 (1997) 1803-1805
95. Rakesh K., and Agrawal D.K. Controlling cytokine signaling by constitutive inhibitors. Biochem Pharmacol 70 5 (2005) 649-657
96. Pillemer B.B., Xu H., Oriss T.B., et al. Deficient SOCS3 expression in CD4+CD25+FoxP3+ regulatory T cells and SOCS3-mediated suppression of Treg function. Eur J Immunol 37 8 (2007) 2082-2089
97. Yu H., Kortylewski M., and Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7 1 (2007) 41-51
98. Turkson J., Zhang S., Palmer J., et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 3 12 (2004) 1533-1542
99. Zhang L., Alizadeh D., Van Handel M., et al. Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice. Glia 57 (2009) 1458-1467
100. Jing N., Li Y., Xu X., et al. Targeting Stat3 with G-quartet oligodeoxynucleotides in human cancer cells. DNA Cell Biol 22 11 (2003) 685-696
101. Leong P.L., Andrews G.A., Johnson D.E., et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A 100 7 (2003) 4138-4143
102. Siddiquee K., Zhang S., Guida W.C., et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A 104 18 (2007) 7391-7396
103. Gu J., Li G., Sun T., et al. Blockage of the STAT3 signaling pathway with a decoy oligonucleotide suppresses growth of human malignant glioma cells. J Neurooncol 89 1 (2008) 9-17
104. Konnikova L., Kotecki M., Kruger M.M., et al. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer 3 (2003) 23
105. Ren W., Duan Y., Yang Y., et al. Down-regulation of Stat3 induces apoptosis of human glioma cell: a potential method to treat brain cancer. Neurol Res 30 3 (2008) 297-301
106. Rahaman S.O., Harbor P.C., Chernova O., et al. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 21 55 (2002) 8404-8413
107. Blaskovich M.A., Sun J., Cantor A., et al. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63 6 (2003) 1270-1279
108. Hussain S.F., Kong L.Y., Jordan J., et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 67 20 (2007) 9630-9636
109. Iwamaru A., Szymanski S., Iwado E., et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26 17 (2007) 2435-2444
110. Cuevas P., Diaz-Gonzalez D., Gimenez-Gallego G., et al. Dihydroxy-2,5 benzenesulphonate (dobesilate) elicits growth arrest and apoptosis in glioma cells. Neurol Res 27 8 (2005) 797-800
111. Rayner A.V., O'Brien J.G., and Schoenbachler B. Behavior disorders of dementia: recognition and treatment. Am Fam Physician 73 4 (2006) 647-652
112. Iwasaki K., Kikuchi H., Miyatake S., et al. Clonal analysis in the ultrastructure of cell-to-cell interaction between a human glioma cell line and autologous tumor-specific cytotoxic T lymphocytes. Cell Immunol 126 1 (1990) 164-175
113. Rosenberg S.A., Lotze M.T., Muul L.M., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313 23 (1985) 1485-1492
114. Jacobs S.K., Wilson D.J., Kornblith P.L., et al. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. Cancer Res 46 4 Pt 2 (1986) 2101-2104
115. Hayes R.L., Koslow M., Hiesiger E.M., et al. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 76 5 (1995) 840-852
116. Yamasaki T., and Kikuchi H. An experimental approach to specific adoptive immunotherapy for malignant brain tumors. Nippon Geka Hokan 58 6 (1989) 485-492
117. Kitahara T., Watanabe O., Yamaura A., et al. Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor. J Neurooncol 4 4 (1987) 329-336
118. Tsurushima H., Liu S.Q., Tuboi K., et al. Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes. Jpn J Cancer Res 90 5 (1999) 536-545
119. Plautz G.E., Miller D.W., Barnett G.H., et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 6 6 (2000) 2209-2218
120. Quattrocchi K.B., Miller C.H., Cush S., et al. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol 45 2 (1999) 141-157